Deborah Heart and Lung Center - Comprehensive Analysis Report

Summary

Deborah Heart and Lung Center stands as a dedicated specialty hospital focused on heart, lung, and vascular diseases. Its foundational mission, "There is no price on life," underscores a deep commitment to providing advanced care universally, irrespective of a patient's financial standing. Since its establishment in 1922, the center has treated a vast number of patients, consistently earning recognition as a leader in clinical outcomes and patient-centered service. It operates as a vital regional safety net and a teaching hospital, aiming to redefine advanced specialty care delivery with a focus on community health and accessibility for all.

1. Strategic Focus & Objectives

Core Objectives

Deborah Heart and Lung Center's core objectives revolve around delivering the highest quality heart, lung, and vascular care in a collaborative and welcoming environment, ensuring access for all patients. Key objectives include:

Universal Access: Providing care regardless of a patient's financial situation, embodying the "No Price on Life" philosophy.

Superior Quality Outcomes: Consistently achieving excellent clinical outcomes through continuous quality improvement, patient safety, and privacy.

Patient-Centered Service: Striving for a customer-driven service model that prioritizes the patient experience.

Community Health: Reimagining the delivery of advanced specialty care with an emphasis on healthy living for all communities.

Regional Leadership: Becoming the premier provider of cardiovascular and pulmonary services in the region.

Strategic Initiatives: Strengthening core pillars including its mission, people-centric culture, and superior quality outcomes.

Access and Education: Improving healthcare access, assisting in care coordination, and enhancing public education and awareness to reduce chronic disease risk and improve management.

Specialization Areas

Deborah Heart and Lung Center specializes in the prevention, diagnosis, research, and treatment of congenital and acquired heart, lung, and vascular diseases in adults. It also extends its expertise to provide outpatient cardiology services for children. The center’s unique value proposition lies in its long-standing humanitarian mission combined with a commitment to cutting-edge research and patient safety.

Target Markets

The primary target markets for Deborah Heart and Lung Center include adults and children requiring specialized care for heart, lung, and vascular conditions. Geographically, it focuses on patients within its service area, which includes Burlington, Camden, Atlantic, Gloucester, Salem, Cumberland, and Cape May Counties in New Jersey, as well as Bucks and Philadelphia Counties in Pennsylvania, through its clinical affiliation with Cleveland Clinic.

2. Financial Overview

Funding History

As a nonprofit organization, Deborah Heart and Lung Center's financial operations are transparent.

Total Funds Raised: The Deborah Hospital Foundation, its philanthropic partner, has consistently secured resources. In 2024, the Foundation provided $6,678,310 in program support.

Significant Gifts: In 2019, the center received a substantial $5 million gift from Gregory Olsen, PhD. This gift was instrumental in launching a project exceeding $50 million.

Fund Utilization: The $5 million gift from Gregory Olsen was part of the Deborah100: The Campaign, a multi-year initiative dedicated to expansion projects, new patient floors featuring private inpatient suites, and significant technology upgrades. This coincided with the hospital's 100th anniversary in 2022.

Impact on Company Growth: These funding initiatives support infrastructure development, technological advancements, and expanded service offerings, directly contributing to the center’s capacity for growth and its ability to provide state-of-the-art care.

For the fiscal year 2024, the center reported the following:

Total Revenues: $239,098,859

Total Expenses: $241,972,280

Total Assets: $204,580,206

Total Liabilities: $103,708,665

3. Product Pipeline

Key Products/Services

Deborah Heart and Lung Center maintains an active clinical research department, involved in over 30 studies, multicenter trials, and registries, exploring new treatments and procedures across various cardiovascular and pulmonary domains.

THOR IDE Study:

Description: A clinical trial assessing the safety and efficacy of the Thor system for treating de novo calcified lesions in infrainguinal arteries, relevant for patients with peripheral artery disease (PAD).

Development Stage: Actively enrolling adult patients.

Target Market/Condition: Adult patients with de novo calcified lesions in infrainguinal arteries (PAD).

Key Features and Benefits: Offers a less invasive approach to address blockages, potentially preventing more extensive surgery.

Integra-D Clinical Trial (Optimizer™ Integra-D Cardiac Contractility Modulation – Defibrillator (CCM-D) device):

Description: Evaluates the safety and effectiveness of the Optimizer™ Integra-D CCM-D device, an investigational technology combining Cardiac Contractility Modulation (CCM) therapy with an implantable cardioverter defibrillator (ICD).

Development Stage: Actively participating in the clinical trial.

Target Market/Condition: Heart failure patients with reduced ejection fraction who require improvement in heart function and protection against sudden cardiac arrest.

Key Features and Benefits: Designed to improve symptoms of heart failure and prevent sudden death by combining therapies that improve heart function and provide defibrillation capabilities.

Ongoing Heart Failure Research: Includes studies on heart failure assessment devices, cardiac resynchronization and device diagnostics, disease management, and clinical outcomes.

Adult Congenital Heart Disease Program: An active program providing specialized care for patients with congenital heart conditions in adulthood.

4. Technology & Innovation

Technology Stack

Deborah Heart and Lung Center leverages advanced technology to enhance both its operational efficiency and patient care delivery.

Electronic Health Record (EHR) System:

Core Platforms: MEDITECH Expanse EHR system.

Proprietary Developments: Launched in 2021 as an upgrade, it integrates inpatient and outpatient areas, simplifies user access with personalized clinician screen layouts, and ensures smooth patient handoffs.

Technical Capabilities: Sophisticated tools for improving quality outcomes, streamlining costs through upgraded metrics tracking, enhanced documentation, charge generation, and common inventory management. It also provides secure electronic health information exchange.

Analytics: Utilizes MEDITECH's Business and Clinical Analytics solution for critical decision-making and monitoring operational efficiency.

Patient Portal: Employs the MEDITECH Expanse patient portal for online pre-registration and access to resources, offering a self-service patient experience.

Conversational Messaging Platform:

Core Platforms: Partnered with Artera for patient communication.

Technical Capabilities: Modernizes communication through conversational messaging and automations, sending proactive notifications and providing advanced reporting and analytics on patient engagement.

Impact: Improved operational efficiency, reduced patient no-shows by 50% (recovering an estimated $215,000 in revenue in 2024), and achieved an 83% patient response rate.

Advanced Diagnostic and Treatment Devices:

Electrophysiology: First in its region to use next-generation defibrillators, including the Unify CRT-D and Fortify ICD (St. Jude Medical).

Technical Capabilities: These devices offer 40 joules of energy, are designed to prevent unnecessary defibrillation, and feature streamlined sizes for smaller incisions. The CRT-D resynchronizes heart chambers for heart failure, while the ICD treats abnormally fast heart rhythms.

Catheter-based Devices:

Cath Labs: Utilizes advanced catheter-based devices for peripheral vascular disease (PVD), such as Frontrunner and Crosser.

Key Features and Benefits: These devices help address blockages and can prevent more invasive surgery.

Novel Blood Test:

Implementation: In January 2026, Deborah became the first hospital in New Jersey to implement Diasorin's LIAISON® MeMed BV® test.

Functionality: This new blood test rapidly distinguishes between bacterial and viral infections.

Benefits: Allows for faster and more accurate treatment decisions.

5. Leadership & Management

Executive Team

Jim Andrews

Position: President and Chief Executive Officer (effective September 9, 2024), also President and CEO of the Deborah Hospital Foundation.

Professional Background: Over two decades of healthcare leadership experience in driving strategic growth, enhancing patient care, and fostering innovation. Previously, Senior Vice President for Heart & Vascular and Neuroscience service lines at RWJBarnabas Health.

Education: Master of Science in Healthcare Leadership from Brown University, Bachelor of Science in Business Management from Babson College.

LinkedIn Profile: [https://www.linkedin.com/in/jim-andrews-mhl-713b106/]

Michael Lieb, FACHE

Position: Executive Vice President and Chief Operating Officer (appointed June 2025).

Professional Background: Over 30 years of senior healthcare leadership across multi-hospital systems, academic medical centers, rural, and critical access hospitals. Previously, interim Vice President of Ambulatory Services at University Hospital in Newark, NJ.

Key Contributions: Oversees day-to-day operations, drives strategic initiatives, and ensures excellence in clinical quality, safety, patient experience, and organizational performance.